Priyanka Ram

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index671citations55works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(32), BRCA gene mutations in cancer(11), Monoclonal and Polyclonal Antibodies Research(10), Genetic factors in colorectal cancer(9), CAR-T cell therapy research(8)

Publications55 total

Data from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Supplementary Figures 1-7 from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Data from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Supplementary Figures 1-7 from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 6 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 7 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 11 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 14 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 7 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 4 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 12 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Ofir Cohen(39), Samuel S. Freeman(39), Nikhil Wagle(39), Nancy U. Lin(39), Heather A. Parsons(38), Justin Rhoades(38), Sarah C. Reed(38), Pedro Exman(38), Kan Xiong(38), Denisse Rotem(38), Melissa E. Hughes(38), Laura C. Collins(38), Kathy D. Miller(38), Brendan Blumenstiel(38), Carrie Cibulskis(38), Donna Neuberg(38), Niall J. Lennon(38), Gavin Ha(38), Daniel G. Stover(38), Atish D. Choudhury(38)